Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

TLDR: Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eriboxin could be a treatment option for advanced soft-tissue sarcoma.

About: This article is published in The Lancet.The article was published on 2016-04-16 and is currently open access. It has received 578 citations till now. The article focuses on the topics: Eribulin & Dacarbazine.

Figures

Table 2: Summary of adverse events (within 30 days of last dose)

Table 1: Baseline patient and disease characteristics

Figure 1: Trial profi le Data cutoff was Jan 2, 2015. ITT=intention-to-treat. *Includes one patient who was assigned to eribulin but treated with dacarbazine.

Figure 2: Overall survival (A) and progression-free survival (B) HR=hazard ratio.

Frequently asked questions

Q1. What have the authors contributed in "Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial" ?

The authors did this randomised, open-label, phase 3 study across 110 study sites in 22 countries. The study is registered with ClinicalTrials. 

Q2. What are the future works in "Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial" ?

On the basis of the strong evidence for its use presented in this study, eribulin merits further exploration in less common subtypes of soft-tissue sarcoma and in earlier lines of treatment, either alone or in combination with other drugs, in future studies. The absence of masking is a potential limitation of this study. The exploratory nature of these endpoints might also be considered to be potential limitations of this study because these can infl uence treatment decisions. Their fi ndings suggest that eribulin might be an important treatment option for patients with previously treated liposarcoma or leiomyosarcoma. 

Q3. What was the primary endpoint of the study?

Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. 

Q4. What is the main endpoint of the study?

Interpretation Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eribulin could be a treatment option for advanced soft-tissue sarcoma.